Financial Performance - Revenue for Q3 2025 was $149.0 million, a 2% decrease from Q3 2024, primarily due to a decline in instrument revenue [4]. - Gross margin decreased to 67% in Q3 2025 from 70% in Q3 2024, attributed to changes in product mix and higher inventory write-downs [5]. - Operating expenses were $132.5 million, a 10% decrease from $147.9 million in Q3 2024, mainly due to lower personnel and legal expenses [6]. - Net loss for Q3 2025 was $27.5 million, compared to a net loss of $35.8 million in Q3 2024 [7]. - Q4 2025 revenue guidance is projected to be between $154 million and $158 million, indicating a 6% decline year-over-year but a 5% sequential growth at the midpoint [9]. - Instruments revenue for Q3 2025 was $12.0 million, down from $19.1 million in Q3 2024, while consumables revenue increased to $127.9 million [18]. - Total revenue for the nine months ended September 30, 2025, was $476.8 million, compared to $445.8 million for the same period in 2024 [18]. Cash and Assets - Cash and cash equivalents and marketable securities totaled $482.1 million as of September 30, 2025, reflecting a $35 million increase from the previous quarter [8]. - Total assets increased to $1,027,361 million as of September 30, 2025, up from $918,636 million on December 31, 2024, representing an increase of approximately 11.9% [21]. - Total current assets rose to $659,827 million, compared to $584,387 million at the end of 2024, reflecting a growth of about 12.9% [21]. - Cash and cash equivalents increased to $432,508 million, up from $344,067 million, marking a significant rise of approximately 25.7% [21]. - Accounts receivable decreased to $43,779 million from $87,862 million, a decline of about 50.1% [21]. - Inventory decreased to $61,956 million from $83,107 million, representing a reduction of approximately 25.5% [21]. Liabilities and Equity - Total liabilities grew to $242,241 million, up from $208,502 million, indicating an increase of around 16.2% [21]. - Total stockholders' equity reached $785,120 million, compared to $710,134 million, showing an increase of approximately 10.5% [21]. - Accrued expenses and other current liabilities decreased to $35,766 million from $41,165 million, a decrease of about 13.1% [21]. - Deferred revenue increased to $22,139 million from $20,658 million, reflecting a growth of approximately 7.1% [21]. - Operating lease right-of-use assets increased to $63,650 million from $57,290 million, indicating a rise of about 11.5% [21]. Product Development - The company launched the next-generation Chromium Flex and Xenium Protein, enhancing capabilities in single cell analysis and spatial multiomics [10]. Regional Performance - The Americas accounted for $79.9 million of total revenue in Q3 2025, with the United States contributing $77.2 million [18].

Exhibit 99.1 Doximity Announces Fiscal 2026 Second Quarter Financial Results Total revenues of $168.5 million, up 23% year-over-year Operating cash flow of $93.9 million, up 37% year-over-year Free cash flow of $91.6 million, up 37% year-over-year SAN FRANCISCO, Calif., November 6, 2025 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30, 2025. "Our platform continues to grow with new AI too ...

Revenue Performance - Total revenue for Q3 2025 was $10.5 million, representing a 9% increase from $9.6 million in Q3 2024[5] - Lab Essentials revenue reached $8.3 million in Q3 2025, up 16% from $7.2 million in Q3 2024[5] - Clinical Solutions revenue was $1.7 million in Q3 2025, down 13% from $2.0 million in Q3 2024[5] Profitability and Loss - Gross profit for Q3 2025 was $3.2 million, with a gross margin of 30.7%, compared to $0.1 million and 0.9% in Q3 2024[6] - Net loss for Q3 2025 was $4.3 million, or negative $0.08 per diluted share, compared to a net loss of $7.6 million, or negative $0.15 per diluted share, in Q3 2024[7] - Adjusted EBITDA for Q3 2025 was negative $1.6 million, an improvement from negative $5.0 million in Q3 2024[8] Cash Flow and Expenses - Operating expenses decreased to $7.2 million in Q3 2025 from $7.5 million in Q3 2024[7] - Free Cash Outflow remained the same at $2.4 million for both Q3 2025 and Q3 2024[8] - Cash used in operating activities for the nine months ended September 30, 2025, was $8,184 million, compared to $11,455 million for the same period in 2024, reflecting a decrease of 28.5%[27] - Free Cash Flow for the nine months ended September 30, 2025, was $(8,984) million, compared to $(12,013) million for the same period in 2024, reflecting an improvement of 25.2%[27] Guidance and Future Outlook - The company reaffirms its 2025 revenue guidance of $39-42 million and anticipates Free Cash Outflow of less than $12 million[9] Balance Sheet and Assets - Total cash and short-term investments were $22.1 million, with total borrowings of $13.2 million at the end of Q3 2025[4] - As of September 30, 2025, total assets decreased to $107,625 million from $118,769 million as of December 31, 2024, representing a decline of approximately 9.5%[24] - Total current liabilities decreased to $6,936 million as of September 30, 2025, from $11,211 million as of December 31, 2024, a reduction of 38.5%[24] - The company had total stockholders' equity of $72,650 million as of September 30, 2025, down from $82,394 million as of December 31, 2024, a decrease of 11.8%[24] Depreciation and Inventory - The company reported a depreciation and amortization expense of $1,591 million for the three months ended September 30, 2025, compared to $1,671 million for the same period in 2024, a decrease of 4.8%[26] - Inventory reserve increased to $732 million for the three months ended September 30, 2025, from $3,339 million in the same period of 2024, indicating a significant reduction in inventory write-downs[26] Improvement in Losses - The net loss for the three months ended September 30, 2025, was $4,286 million, an improvement from a net loss of $7,565 million for the same period in 2024, indicating a reduction of 43.1%[26] - Adjusted EBITDA for the three months ended September 30, 2025, was $(1,576) million, compared to $(5,001) million for the same period in 2024, showing an improvement of 68.5%[27] - Cash and cash equivalents at the end of the period were $3,204 million, down from $6,145 million at the end of the previous year, a decline of 47.9%[26]

Revenue Performance - Total revenue for the three months ended September 30, 2025, was less than $0.1 million, with royalty revenue remaining consistent at $28,000, while product revenue dropped to zero from $2,000 in the same period of 2024[120] - Royalty revenue for the six months ended September 30, 2025, increased by $12,000 or 23% to $65,000 compared to $53,000 in the same period of 2024[126] - Total revenue for the six months ended September 30, 2025, was $0.1 million, consistent with the same period in 2024[127] Expenses - Research and development expenses for the three months ended September 30, 2025, were $923,000, a decrease of approximately $61,000 or 6% from the prior year, attributed to a reduction in average full-time staff from fourteen to nine[122] - Selling, general and administrative expenses increased by approximately $87,000 or 5% to $1,740,000 for the three months ended September 30, 2025, despite a decrease in average full-time staff from five to four[124] - Research and development expenses for the six months ended September 30, 2025, were $1,924,000, a decrease of $462,000 or 19% from $2,386,000 in the prior year[126] - Research and development expenses decreased by $0.5 million, or approximately 19%, to $1.9 million for the six months ended September 30, 2025, compared to $2.4 million in 2024[129] - Selling, general and administrative expenses remained approximately the same at $3.7 million for the six months ended September 30, 2025, compared to $3.7 million in 2024[131] Cash Flow and Financial Position - Net cash used in operating activities increased to approximately $6.3 million for the six months ended September 30, 2025, from $5.6 million in 2024[137] - Cash and cash equivalents as of September 30, 2025, were approximately $6.7 million, down from $11.3 million at March 31, 2025[134] - The accumulated deficit increased to $347.5 million as of September 30, 2025, compared to $342.2 million at March 31, 2025[134] - Total current assets were approximately $7.6 million and current liabilities were approximately $2.4 million, resulting in working capital of $5.2 million as of September 30, 2025[135] - Net cash provided by financing activities was $1.7 million for the six months ended September 30, 2025, down from $5.9 million in 2024[139] Future Outlook and Developments - The company anticipates having a product candidate ready for an Investigational New Drug (IND) application with the FDA by December 2026[112] - The liver predictive power of the company's platform was shown to be 87.5% for liver toxicity cases, with a specificity of 100%[113] - The company sold its FXR program for $10 million, with potential future milestones of up to $50 million based on key development and regulatory achievements[110] - The company plans to start a Phase 2a clinical trial for FXR314 in ulcerative colitis in the calendar year 2025[109] - The company has advanced a new chemical entity (NCE) drug program for inflammatory bowel disease, moving from in-silico to medicinal chemistry stages[109] - The company expects total operating expenses for the fiscal year ending March 31, 2026, to be between $10 million and $12 million[141] - As of September 30, 2025, approximately $140.1 million was available for future offerings under the 2024 Shelf registration[145]

Revenue Performance - Total revenues for Q3 2025 reached $332.6 million, a 9.6% increase from $303.3 million in Q3 2024[37] - Total revenues for the three months ended September 30, 2025, were $332,638 thousand, representing a 9.6% increase from $303,316 thousand in the same period of 2024[145] - Total revenues for the nine months ended September 30, 2025, reached $927.15 million, compared to $865.26 million in 2024, reflecting growth in both service and product revenues[205] - Revenues increased by 9.7% to $332.6 million in Q3 2025 from $303.3 million in Q3 2024, driven by GigaCloud Marketplace growth[172] Service and Product Revenues - Service revenues decreased slightly to $108.4 million, down from $110.3 million year-over-year[37] - Product revenues increased by 16.2% to $224.3 million compared to $193.0 million in the same quarter last year[37] - Service revenues for the three months ended September 30, 2025, were $108,370,000, slightly down from $110,340,000 in the same period of 2024[70] - Product revenues for the same period were $224,268 thousand, an increase of 16.2% from $192,976 thousand year-over-year[79] - The Group's total product revenues for the nine months ended September 30, 2025, were $627.8 million, an increase from $582.5 million in 2024, representing a growth of 7.8%[105] Profitability Metrics - Gross profit for Q3 2025 was $77.0 million, slightly down from $77.3 million in Q3 2024[37] - Net income for Q3 2025 was $37.2 million, a decrease from $40.7 million in Q3 2024[37] - Adjusted EBITDA for the three months ended September 30, 2025, was $43.4 million, down from $48.8 million in the same period of 2024[1] - The gross profit margin for Q3 2025 was 23.2%, slightly down from 25.5% in Q3 2024[171] Cash Flow and Liquidity - Cash provided by operating activities increased to $126,292,000 for the nine months ended September 30, 2025, up from $89,660,000 in 2024, indicating a significant improvement in operational cash flow[51] - Total cash, cash equivalents, and restricted cash at the end of the period was $335,554,000, compared to $218,327,000 at the end of September 30, 2024, reflecting a year-over-year increase of approximately 53.8%[51] - Cash and cash equivalents as of September 30, 2025 totaled $334.9 million, an increase from $218.3 million at the end of September 2024[209][213] Shareholder Equity and Repurchases - Shareholders' equity increased to $457.3 million, up from $405.2 million at the end of 2024[33] - The company repurchased ordinary shares amounting to $57,373,000 during the nine months ended September 30, 2025[51] - The company has $99.7 million remaining available for Class A ordinary share repurchases as of September 30, 2025[98] Expenses and Cost Management - Total operating expenses for the three months ended September 30, 2025, were $36,529 thousand, representing 11.0% of total revenues, compared to 12.0% in Q3 2024[170] - Selling and marketing expenses increased to $25,477 thousand (7.7% of total revenues) in Q3 2025 from $18,605 thousand (6.1%) in Q3 2024[171] - General and administrative expenses decreased to $8,511 thousand (2.6% of total revenues) in Q3 2025 from $15,296 thousand (5.0%) in Q3 2024[171] - Research and development expenses remained stable at $2,534 thousand (0.8% of total revenues) in Q3 2025, compared to $2,582 thousand (0.9%) in Q3 2024[171] Assets and Liabilities - Total assets increased to $1.124 billion as of September 30, 2025, up from $1.070 billion at the end of 2024[33] - Total liabilities remained relatively stable at $666.8 million, compared to $665.3 million at the end of 2024[33] - The total lease liabilities as of September 30, 2025, were $461,996 thousand, a decrease from $484,278 thousand at the end of 2024[95] Market and Operational Insights - GigaCloud Marketplace GMV increased to $1,488.5 million for the 12 months ended September 30, 2025, representing a growth of 20.7% from $1,233.6 million in 2024[122] - The number of active 3P sellers rose to 1,232, marking a 17.2% increase from 1,051 in the previous year[124] - Active buyers increased to 11,419, reflecting a 33.8% growth compared to 8,535 in the prior year[126] - The company operates 35 fulfillment centers with a total gross floor area of approximately 10.9 million square feet across five countries as of September 30, 2025[140] Future Outlook and Strategic Plans - The Group plans to acquire New Classic Home Furnishings, Inc. for $18 million in cash, enhancing its domestic distribution capabilities[112] - Future acquisitions may be considered to enhance the number of sellers and buyers, as well as to broaden product offerings and logistics capabilities[131] - The company expects to utilize excess fulfillment capacity to offer third-party logistics services opportunistically as the GigaCloud Marketplace grows[149] - The company plans to continue expanding its logistics capacity to support marketplace growth and fulfill customer needs[149]

Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related ...

Financial Performance - aTyr Pharma reported a consolidated net loss of $25.7 million for Q3 2025, compared to a net loss of $17.3 million in Q3 2024, reflecting an increase of 48% year-over-year [14]. - Total revenues for Q3 2025 were $190,000, compared to $235,000 in Q3 2024, indicating a decrease of 19% year-over-year [14]. - General and administrative expenses for Q3 2025 were $4.8 million, compared to $3.3 million in Q3 2024, reflecting a 44% increase [14]. - The total operating expenses for Q3 2025 were $26.9 million, up from $18.1 million in Q3 2024, marking a 48% increase [14]. Research and Development - Research and development expenses for Q3 2025 were $22.1 million, up from $14.8 million in Q3 2024, representing a 49% increase [14]. - The Phase 3 EFZO-FIT™ study did not meet its primary endpoint but showed clinical benefits for the 5.0 mg/kg efzofitimod group across multiple efficacy measures [7]. - Enrollment in the Phase 2 EFZO-CONNECT™ study is expected to be completed in the first half of 2026, with promising interim data reported earlier [2]. - The company presented results from the Phase 3 EFZO-FIT™ study at the European Respiratory Society Congress 2025, highlighting its significance in the field of pulmonary sarcoidosis [7]. Future Plans - aTyr Pharma plans to meet with the FDA in Q1 2026 to discuss the path forward for efzofitimod in pulmonary sarcoidosis [4]. - The company ended Q3 2025 with $92.9 million in cash, cash equivalents, restricted cash, and investments, an increase from $75.1 million at the end of 2024 [16].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 28, 2025 BLOOMIN' BRANDS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Delaware 20 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Mark One) Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37809 METAVIA INC. (Exact name of Registrant as specified in its charter) Delaware 47-2389984 (State or othe ...

Revenue and Financial Performance - The company has not generated any revenues from product sales to date and does not expect to in the future[100] - Total revenue for the nine months ended September 30, 2025, was $0, a decrease of $6.99 million compared to $6.99 million in the same period of 2024[127] - The company reported a net loss of $19.3 million for the nine months ended September 30, 2025, compared to a net loss of $21.2 million for the same period in 2024[142] - The net loss before taxes for the three months ended September 30, 2025, was $7.2 million, a reduction of $5.1 million compared to a net loss of $12.2 million in the same period of 2024[120] Expenses - Research and development expenses are primarily incurred for clinical trial activities and are expensed as incurred[111] - Research and development expenses for the three months ended September 30, 2025, were $2.2 million, down 73% from $8.3 million in the same period of 2024[122] - Research and development expenses for the nine months ended September 30, 2025, were $11.1 million, a decrease of 44% from $19.9 million in the same period of 2024[130] - General and administrative expenses include costs for operational activities such as accounting and legal services[113] - General and administrative expenses for the three months ended September 30, 2025, increased to $5.3 million, up 73% from $3.1 million in the same period of 2024[123] - General and administrative expenses for the nine months ended September 30, 2025, were $11.3 million, an increase of 14% from $9.9 million in the same period of 2024[131] - Professional and consultant fees for the nine months ended September 30, 2025, increased by $3.6 million to $6.0 million, primarily due to legal and professional fees associated with the XOMA Transaction[131] Cash Flow and Liquidity - Cash and cash equivalents totaled $49.7 million as of September 30, 2025, which is expected to be sufficient to fund planned expenditures for at least the next twelve months[140] - Net cash used in operating activities was $(30.3) million for the nine months ended September 30, 2025, compared to $(19.1) million for the same period in 2024, reflecting an increase in cash outflow of $(11.2) million[141] - Net cash provided by investing activities was $40.4 million for the nine months ended September 30, 2025, significantly higher than $1.5 million in the same period of 2024, driven by $40.1 million from maturities of investments[146] - The company experienced a net increase in cash and cash equivalents of $10.1 million for the nine months ended September 30, 2025, compared to a net decrease of $(17.5) million in the same period of 2024, reflecting a positive cash flow change of $27.6 million[141] Agreements and Collaborations - A share purchase agreement with XOMA Royalty Corporation was entered into, offering $1.04 per share plus a contingent value right[92] - The minimum closing net cash condition for the XOMA transaction was reduced from $31.5 million to $24.5 million[92] - The company received a $50 million nonrefundable upfront payment from Pfizer in October 2022 as part of a collaboration agreement[101] - Pfizer is expected to pay up to approximately $650 million upon achieving development, regulatory, and commercial milestones[101] - Under the Pfizer Agreement, the company received a nonrefundable up-front payment of $50.0 million in October 2022 and a clinical milestone payment of $7.0 million in March 2024[137] - The company anticipates no additional reimbursement for agreed-to services under the Pfizer Agreement at this time[137] Restructuring and Trials - A restructuring plan was adopted in February 2025, resulting in a workforce reduction of approximately 30%[96] - The company incurred $0.3 million in costs related to the discontinuation of the Phase 1 trial of LAVA-1266[95] Other Income and Losses - Gain on extinguishment of borrowings recognized in the nine months ended September 30, 2025, was $5.2 million, contributing to total other income of $3.4 million[126] - Other income (expense), net increased to $3.4 million for the nine months ended September 30, 2025, up from $1.8 million in the same period of 2024, primarily due to a $5.2 million gain on extinguishment of borrowings[134] - Foreign currency exchange loss for the nine months ended September 30, 2025, was $3.5 million, an increase of $2.8 million compared to a loss of $0.7 million in the same period of 2024[126] Taxation - Income tax expense for the three months ended September 30, 2025, was $0.1 million, consistent with the same period in 2024[117] Contractual Obligations - There were no material changes to the company's contractual obligations and commitments during the three and nine months ended September 30, 2025, compared to the previous year[139]